Rosa Miceli

856 total citations · 2 hit papers
15 papers, 575 citations indexed

About

Rosa Miceli is a scholar working on Psychiatry and Mental health, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Rosa Miceli has authored 15 papers receiving a total of 575 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Psychiatry and Mental health, 7 papers in Surgery and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Rosa Miceli's work include Migraine and Headache Studies (12 papers), Cardiovascular Syncope and Autonomic Disorders (4 papers) and Sympathectomy and Hyperhidrosis Treatments (3 papers). Rosa Miceli is often cited by papers focused on Migraine and Headache Studies (12 papers), Cardiovascular Syncope and Autonomic Disorders (4 papers) and Sympathectomy and Hyperhidrosis Treatments (3 papers). Rosa Miceli collaborates with scholars based in United States, Germany and Denmark. Rosa Miceli's co-authors include Joel M. Trugman, Michelle Finnegan, Lawrence Severt, Hua Guo, Richard B. Lipton, Jessica Ailani, Peter J. Goadsby, Veronica Mas Casullo, Michael W. Dunne and Alena Jandourek and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Neurology.

In The Last Decade

Rosa Miceli

12 papers receiving 565 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atogepant for the Preventive Treatment of Migraine

2021 194 citations Jessica Ailani, Richard B. Lipton et al. New England Journal of Medicine profile →
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

2023 75 citations Patricia Pozo‐Rosich, Jessica Ailani et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rosa Miceli United States	8	393	267	140	126	108	15	575
A M Segers United States	9	454 1.2×	156 0.6×	178 1.3×	140 1.1×	13 0.1×	15	565
Joseph Paternoster United States	7	234 0.6×	128 0.5×	124 0.9×	89 0.7×	6 0.1×	7	325
Monica Siniscalchi Italy	14	154 0.4×	69 0.3×	71 0.5×	197 1.6×	26 0.2×	25	851
John Noviasky United States	11	148 0.4×	60 0.2×	63 0.5×	30 0.2×	18 0.2×	33	414
N. González-García Spain	10	167 0.4×	93 0.3×	46 0.3×	13 0.1×	65 0.6×	37	388
Asad Jehangir United States	15	47 0.1×	22 0.1×	113 0.8×	246 2.0×	96 0.9×	55	649
Jatinder Gill United States	16	29 0.1×	194 0.7×	91 0.7×	256 2.0×	22 0.2×	64	842
Khalil El‐Chammas United States	13	101 0.3×	23 0.1×	69 0.5×	206 1.6×	5 0.0×	45	479
Anh L. Ngo United States	11	45 0.1×	26 0.1×	94 0.7×	69 0.5×	13 0.1×	19	372
Kamal Masaki United States	8	78 0.2×	99 0.4×	119 0.8×	14 0.1×	21 0.2×	18	409

Countries citing papers authored by Rosa Miceli

Since Specialization

Citations

This map shows the geographic impact of Rosa Miceli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosa Miceli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosa Miceli more than expected).

Fields of papers citing papers by Rosa Miceli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosa Miceli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosa Miceli. The network helps show where Rosa Miceli may publish in the future.

Co-authorship network of co-authors of Rosa Miceli

This figure shows the co-authorship network connecting the top 25 collaborators of Rosa Miceli. A scholar is included among the top collaborators of Rosa Miceli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosa Miceli. Rosa Miceli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

D’Haens, Geert, Silvio Danese, Remo Panaccione, et al.. (2025). Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis. Journal of Crohn s and Colitis. 19(6).

Pozo‐Rosich, Patricia, Jessica Ailani, Messoud Ashina, et al.. (2023). Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 402(10404). 775–785. 75 indexed citations breakdown →

Ashina, Messoud, Stewart J. Tepper, Uwe Reuter, et al.. (2023). Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial. Headache The Journal of Head and Face Pain. 63(1). 79–88. 36 indexed citations

Klein, Brad, Rosa Miceli, Lawrence Severt, et al.. (2023). Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia. 43(1). 2205173306–2205173306. 17 indexed citations

Ashina, Messoud, Stewart J. Tepper, Uwe Reuter, et al.. (2022). Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial (P1-2.001). Neurology. 98(18_supplement). 1 indexed citations

Klein, Brad, Rosa Miceli, Lawrence Severt, et al.. (2022). Evaluation of the Long-Term Safety and Tolerability of Oral Atogepant 60 Mg Once Daily for Preventive Treatment of Migraine: A Phase 3, 40-Week, Multicenter Extension to the Advance Trial (P3-2.001). Neurology. 98(18_supplement).

Lipton, Richard B., Patricia Pozo‐Rosich, Andrew Blumenfeld, et al.. (2022). Rates of Response to Atogepant for Migraine Prophylaxis Among Adults. JAMA Network Open. 5(6). e2215499–e2215499. 12 indexed citations

Ashina, Messoud, Stewart J. Tepper, Uwe Reuter, et al.. (2021). Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine (2664). Neurology. 96(15_supplement). 5 indexed citations

Ashina, Messoud, SJ Tepper, Uwe Reuter, et al.. (2021). P.030 Long-term Safety and Tolerability of Atogepant 60 mg Following Once-Daily Dosing Over 1 Year for the Preventive Treatment of Migraine. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 48(s3). S28–S29. 2 indexed citations

10.

Ailani, Jessica, Richard B. Lipton, Peter J. Goadsby, et al.. (2021). Atogepant for the Preventive Treatment of Migraine. New England Journal of Medicine. 385(8). 695–706. 194 indexed citations breakdown →

11.

Ailani, Jessica, Richard B. Lipton, Peter J. Goadsby, et al.. (2021). Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine (1494). Neurology. 96(15_supplement).

12.

Schwedt, Todd J., Richard B. Lipton, Jessica Ailani, et al.. (2021). Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia. 42(1). 3–11. 45 indexed citations

13.

Goadsby, Peter J., Stewart J. Tepper, Paul B. Watkins, et al.. (2019). Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults. Cephalalgia. 39(14). 1753–1761. 35 indexed citations

14.

Trugman, Joel M., Peter J. Goadsby, Stewart J. Tepper, et al.. (2019). Safety and Tolerability of Ubrogepant Following Intermittent, High Frequency Dosing (S17.009). Neurology. 92(15_supplement). 2 indexed citations

15.

Rappo, Urania, Sailaja Puttagunta, Alena Jandourek, et al.. (2018). Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety. Open Forum Infectious Diseases. 6(1). ofy331–ofy331. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact